Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Capitalized research and development costs	$ 38,850	$ 30,019
Net operating loss carryforwards	1,436	85,622
Orphan drug credit carryforwards	2,193	23,790
Research and development credit carryforwards	422	11,569
Intangible assets	2,705	6,291
Accrued expenses and other	6,760	6,740
Operating lease liability	2,287	2,911
Gross deferred tax assets	54,653	166,942
Valuation allowance	(51,753)	(164,483)
Net deferred tax assets	2,900	2,459
Deferred tax liability	(2,900)	(2,459)
Net deferred tax assets	$ 0	$ 0